Parexel International Corp. (NASDAQ:PRXL)‘s stock had its “buy” rating reiterated by investment analysts at Credit Suisse Group AG in a research report issued to clients and investors on Wednesday.

Other equities research analysts have also recently issued research reports about the stock. Evercore ISI restated a “buy” rating and issued a $78.50 target price (up previously from $71.00) on shares of Parexel International Corp. in a report on Friday, August 5th. Jefferies Group lifted their price target on shares of Parexel International Corp. from $70.00 to $72.50 and gave the stock a “hold” rating in a research note on Friday, August 5th. Deutsche Bank AG lifted their price target on shares of Parexel International Corp. from $65.00 to $71.00 and gave the stock a “hold” rating in a research note on Friday, August 5th. Citigroup Inc. lifted their price target on shares of Parexel International Corp. from $74.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, August 5th. Finally, SunTrust Banks Inc. cut shares of Parexel International Corp. from a “buy” rating to a “hold” rating and dropped their price target for the stock from $80.00 to $60.00 in a research note on Friday, November 11th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $67.00.

Analyst Recommendations for Parexel International Corp. (NASDAQ:PRXL)

Parexel International Corp. (NASDAQ:PRXL) opened at 56.47 on Wednesday. The stock has a market capitalization of $3.00 billion, a price-to-earnings ratio of 17.81 and a beta of 0.91. The company has a 50-day moving average of $63.26 and a 200 day moving average of $64.17. Parexel International Corp. has a 12 month low of $51.16 and a 12 month high of $71.13.

Parexel International Corp. (NASDAQ:PRXL) last issued its earnings results on Wednesday, October 26th. The company reported $0.76 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.86 by $0.10. Parexel International Corp. had a return on equity of 30.68% and a net margin of 7.09%. The company earned $500.90 million during the quarter, compared to analysts’ expectations of $525.15 million. During the same quarter in the prior year, the business posted $0.70 EPS. The company’s revenue for the quarter was down 2.2% compared to the same quarter last year. On average, equities research analysts anticipate that Parexel International Corp. will post $3.76 earnings per share for the current fiscal year.

A number of hedge funds have recently made changes to their positions in PRXL. UBS Asset Management Americas Inc. increased its stake in shares of Parexel International Corp. by 39.8% in the first quarter. UBS Asset Management Americas Inc. now owns 153,597 shares of the company’s stock worth $9,635,000 after buying an additional 43,718 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Parexel International Corp. by 7.2% in the first quarter. Geode Capital Management LLC now owns 404,974 shares of the company’s stock worth $25,404,000 after buying an additional 27,205 shares in the last quarter. A.R.T. Advisors LLC bought a new stake in shares of Parexel International Corp. during the first quarter worth about $884,000. Metropolitan Life Insurance Co. NY increased its stake in shares of Parexel International Corp. by 4.1% in the first quarter. Metropolitan Life Insurance Co. NY now owns 86,769 shares of the company’s stock worth $5,443,000 after buying an additional 3,389 shares in the last quarter. Finally, Magnetar Financial LLC bought a new stake in shares of Parexel International Corp. during the first quarter worth about $215,000. Institutional investors own 95.54% of the company’s stock.

About Parexel International Corp.

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company, which provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology and medical device industries across the world.

5 Day Chart for NASDAQ:PRXL

Receive News & Stock Ratings for Parexel International Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parexel International Corp. and related stocks with our FREE daily email newsletter.